Resources
67 Results (showing 31 - 40)
Results sorted by posted date (newest first)
Results sorted by posted date (newest first)
Posted 10/5/2021 (updated 4/3/2024)
This webinar focused on the crucial role of the emergency department (ED) in recognizing and treating opioid use disorder (OUD) patients with evidence-based medications for addiction treatment. Gail D’Onofrio, MD, discussed her pioneering work in creating the evidence for initiating ED buprenorphine treatment with ED patients presenting with opioid use disorder. Overall, the opioid epidemic intertwined with the COVID-19 pandemic has greatly escalated the need to mitigate the morbidity and mortality associated with the rising rate of fentanyl use. Data supporting the use of buprenorphine in the ED setting as well as the consequences of not initiating treatment will be discussed. While the use of ED prescribed buprenorphine has increased, universal adoption has lagged. Barriers to implementation of ED buprenorphine were discussed as well as strategies to overcome these challenges. Components of successful integration of an ED program with community partnerships was outlined. Current research by emergency physicians regarding innovative strategies such as high-dose buprenorphine inductions and use of extended release 7-day formulation of buprenorphine will be discussed. Initiation buprenorphine effectively, reduces withdrawal symptoms, improves adherence to treatment, and saves lives.
Posted 9/22/2021 (updated 4/3/2024)
PCSS's PCSS-Implementation (PCSS-I) initiative is here to support clinicians and their clinical programs by implementing medications for opioid use disorder (MOUD) into your practice.
PCSS-I has clinical and implementation experts as PCSS-I Facilitators available to work with you and your team to develop strategies tailored specifically to support your needs. There is no cost to participate.
Posted 9/1/2021 (updated 4/2/2024)
Posted 8/4/2021 (updated 4/2/2024)
Posted 8/4/2021 (updated 4/2/2024)
Posted 8/4/2021 (updated 4/2/2024)
Posted 7/19/2021 (updated 4/2/2024)
Buprenorphine/naloxone, an evidence-based treatment for opioid use disorder, is sometimes diverted for non-medical use. In Rhode Island, the prevalence of opioid use and, more recently, of fentanyl in the illicit drug supply is driving overdose fatalities, which increases the need for treatment and raises questions about the changing role of diverted medication in shaping overdose risk.
Posted 7/7/2021 (updated 4/2/2024)
This presentation highlighted the intersection of discrimination, women, substance use and reproductive rights from historical and current perspectives. It then provided methods and techniques for eliminating stigma and discrimination on a provider-patient level and provide an opportunity for the audience to practice compassionate care.
Posted 6/30/2021 (updated 4/2/2024)
In this context, the overarching aim of this document is to inform and encourage governments, policy–makers, and other partners to take the necessary actions to implement evidence-based prevention strategies and treatment services for substance use disorders in order to provide everybody, girls as well as boys, and women as well as men, with the skills and opportunities to prevent the initiation of unhealthy behaviours and, in case of individuals who use drugs and suffer from drug use disorders, with the optimal support for improving their life circumstances.
Engagement in drug treatment following nonfatal overdose among people who inject drugs in Appalachia
Posted 6/2/2021 (updated 4/10/2024)
Immediately after experiencing a non-fatal overdose, many people who inject drugs (PWID) engage in harm-minimizing behavior change, including engagement in drug treatment. To inform the implementation of tailored interventions designed to facilitate drug treatment engagement in rural communities, we sought to identify correlates of starting any form of drug treatment after their most recent overdose among PWID who reside in a rural county in West Virginia.